ArticleWellcome open research2024
Glucose metabolism disorders and changes in cardiovascular risk among adult Peruvian population.
Article in Wellcome open research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rates of cardiovascular diseases are increasing annually, and glucose metabolism disorders play an important role in cardiovascular risk. This study aimed to assess changes in cardiovascular risk over time according to the levels of blood glucose, especially prediabetes and type 2 diabetes. Methods: Prospective cohort study conducted in the northern Peru. Two were the outcomes of interest, evaluated at the cohort's baseline and six years after: cardiovascular risk (in percentage), defined using the laboratory-free risk score (HEARTS from the World Health Organization), and the mean arterial pressure (in mmHg); whereas the exposure was the glucose metabolism disorder at cohort's baseline, especially prediabetes and type 2 diabetes, compared to normoglycaemia. Associations were evaluated using mixed linear regression models, and coefficients (β) and 95% confidence intervals (95% CI) were reported. Results: A total of 1607 subjects were recruited, with a mean age of 48.0 (standard deviation [SD]: 10.5) years, and 50.3% women. Baseline prevalence of prediabetes and type 2 diabetes was 16.9% (95%CI: 15.1%-18.9%) and 11.0% (95%CI: 9.5%-12.6%), respectively; whereas the average of the cardiovascular risk and mean arterial pressure was 3.0% (SD: 2.5%) and 93.1 (SD: 11.9) mmHg, respectively. At baseline, those with prediabetes and type 2 diabetes had a higher cardiovascular risk (0.31% and 0.33%, respectively) and a higher mean arterial pressure (3.3 and 4.2 mmHg, respectively) than those with normal glycaemia. No significant change was found in cardiovascular risk between baseline and follow-up; however, there was a reduction in mean arterial pressure levels, greater among those with normoglycaemia than in cases of prediabetes and type 2 diabetes. Conclusions: Glucose metabolism disorders were associated with an increased cardiovascular risk and mean arterial pressure at baseline, but only with higher levels of mean arterial pressure at follow-up. These findings suggest the need for cardiovascular risk assessment in patients with prediabetes and type 2 diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.